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Insights into the pathogenesis of nicotine 
addiction. Could a salivary biosensor be useful 
in Nicotine Replacement Therapy (NRT)? 
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Abstract Nicotine has gained the attention of the medical community due to its insidious 
addictive mechanisms which lead to chronic consumption. The multitude of compounds 
derived from tobacco smoke have local and systemic negative impacts, resulting in a large 
number of smoking-related pathologies. The present review offers insights into nicotine 
addiction physiopathology, as well as social and medical implications, with emphasis on 
its correlation with Advanced Glycation End Products (AGEs). Therapeutic strategies and 
new approaches to nicotine assessment and cessation treatment are discussed, noting that 
such strategies could take into account the possibility of slow and gradual nicotine release 
from a device attached to a prosthetic piece, based on salivary nicotine-concentration 
feedback. This approach could offer real-time and home-based self-therapy monitoring by 
the physician and the patient for follow-up and improve long-term cessation treatment 
success- Graphical abstract. 
Keywords  Pathogenesis, nicotine addiction, salivary biosensor, Nicotine Replacement Therapy, NRT 
Highlights ✓ Smoking addiction has strong pharmacological, psycho-social, and media support. 
✓ The development of a double-effect salivary biosensor could represent a useful approach 
in nicotine addiction therapy. 
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Introduction 
Nicotine, with the molecular formula C10H14N2 and 
IUPAC name 3-[(2S)-1-methylpyrrolidin-2-yl]pyridine, is 
a natural alkaloid found in the tobacco plant, Nicotiana 
tabacum (1). It has been grown in Native America since 
1400 BCE and then brought to Europe via King Philip the 
2nd of Spain, through his Spanish Chronicler Hernández de 
Boncalo. The name “cigar” is derived from “cicadas,” the 
insects that caused plague in the tobacco cultures (2, 3). 
Over time, nicotine has been used in trading, as a 
ceremonial tool, as a manner of socializing, for pleasure or 
relaxation, and for its therapeutic potential in systemic 
diseases. Nicotine’s hazard consists in the fact that it is 
being used both as an addictive substance and as a 
medication in smoking cessation therapies. The purpose of 
the present paper is to provide an update regarding the 
molecular and pathogenic mechanisms of smoking 
addiction, with emphasis on its correlation with Advanced 
Glycation End Products (AGEs). We also discuss smoking 
cessation strategies and include reference to an innovative 
approach that associates nicotine addiction therapy with a 
biosensor inserted in a prosthetic piece, used both as a real-
time analyzer and as a treatment option. 
Materials and Methods 
This paper is a narrative review of studies involving 
molecular and pathogenic mechanisms of nicotine 
addiction, nicotine metabolism, medical consequences, 
smoke-derived AGEs, cessation treatment options and 
alternatives, and innovative approaches in nicotine 
replacement therapy.  
The authors used “PUBMED” and MeSH to gather 
published papers on the above-mentioned aspects. The 
following keyword associations were used: “nicotine 
addiction”, “nicotine” AND “smoking”, “nicotine” AND 
“pathogenic mechanism”, “nicotine” AND “genetic 
determinism”, “nicotine” AND “metabolism”, “smoking” 
OR “nicotine” AND “AGEs”, “smoking” OR “nicotine” 
AND “disease”, “smoking cessation” AND “Nicotine 
Replacement Therapy (NRT)” OR “saliva”, “smoking 
cessation” AND “salivary biosensor”.  
Inclusion criteria were free full-text articles in English, 
Spanish, or Portuguese. Human and animal model studies 
were both included. Only papers from 2000 and onward 
were included.  
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Results 
1. Nicotine addiction  
1.1 Nicotine and smoking 
Tobacco combustion produces carcinogenic 
compounds such as benzene, formaldehyde, benzapyrene, 
carbon monoxide, and cyanide asphyxiants, acrolein, 
polonium, as well as tobacco-derived pro-inflammatory 
advanced glycation end-products (AGEs) (4). Lewis et al. 
identified three types of smoking: active smoking, passive 
smoking or second hand smoke (SHS), and third hand 
smoke (THS), referring to the oxidized compounds that 
turn into carcinogens, along with tobacco-derived 
nitrosamines, polycyclic aromatic hydrocarbons (PAH), 
deposited on objects and surfaces humans come in contact 
with, which can also be inhaled, absorbed through the skin, 
or ingested (4). THS, also named Residual tobacco smoke 
or Aged tobacco smoke, has been measured using liquid or 
gas chromatography, along with mass spectrometry and 
has a 6-month lifetime in indoor spaces and on surfaces. 
These residuals induce DNA alteration, cytotoxicity, 
increased exhaled Nitric Oxide (NO), liver metabolism 
dysregulation, and thrombosis.  
DiFranza and co-workers elaborated a sequence of 
wanting-craving-needing smoking pattern in chronic 
consumers (5). The authors stated that in the first stage of 
nicotine dependence, the early symptom is to want a 
cigarette, the second stage is an intense craving for a 
cigarette, which disturbs daily activity and thoughts, and 
the third stage is needing, an independent intense demand. 
The period of latency after smoking a cigarette is followed 
by an active symptomatic stage with manifestations such 
as anxiety, anger, restlessness, insomnia, difficulty in 
focusing, and increased appetite. These researchers also 
found that nicotine dependence is suggested by the 
shortening of the latency time (6). Cerebral stimuli are 
driven towards the increase in tobacco input, to maintain 
balance, and the latency period thus decreases in time, 
because nicotine’s half-life is approximately two hours. 
Hormones have a modulating effect on nicotine via 
dopamine, and one hormone, estrogen, is known to 
influence time perception and cognition. Specifically, time 
can be perceived as either faster or slower, an important 
aspect regarding the perceived time period between two 
smoked cigarettes. Cognition may be affected in terms of 
decision making and delay discounting (7). Females 
metabolize nicotine and cotinine faster than men, and their 
metabolism is influenced by hormonal therapy, with oral 
contraceptives slowing tobacco smoke-derived compound 
disintegration (8, 9). A study conducted on active smokers, 
aged 18 to 65 years, with a history of at least 10 
cigarettes/day for at least 6 months, demonstrated that men 
overestimated the abstinence period compared to women 
(10) (Figure 2).      
 
Figure 1.  Review extraction - data methodology chart 




Figure 2. Nicotine addiction 
1.2 Pathogenic molecular mechanisms of nicotine 
addiction 
Nicotine enters blood circulation and binds to pre- or 
postsynaptic acetylcholine receptors (nAChR); these 
receptors are responsible for acetylcholine (Ach), 
dopamine (DA), serotonin, and norepinephrine release. In 
the brain, the most expressed receptors are α4β2 and α7 
nAChR (11).  When ventral tegmental area (VTA) 
DAα4β2 nAChR is stimulated by nicotine, VTA cells enter 
a phasic condition, with increased DA release in the 
nucleus accumbens (NAc) and prefrontal cortex, and 
through this mechanism, nicotine mediates relaxing and 
pleasure effects, considered to be the key point in nicotine 
addiction (12). Nicotine also stimulates μ-opioid 
receptors (MOR) from gamma-Aminobutyric acid 
(GABA) in the VTA area, decreasing GABA secretion and 
increasing DA release from NAC (11). Molas et al. 
demonstrated that the interpeduncular nucleus (IPN) axis 
from the medial habenula (mHb) regulates acute nicotine 
activity, due to its high nAChRs concentration (13). IPN 
controls fear and anxiety-related reflexes, which are among 
the nicotine withdrawal effects and are also nAChR 
mediated. In chronic consumers, nAChRs are regulated by 
either cholinergic or GABA neuron sub-populations of 
mHb-IPN, which increase the parasympathetic activity and 
lead to IPN stimulation as a final result, increasing 
withdrawal symptoms.  
1.3 Nicotine metabolism 
The oral mucosa absorption of nicotine and 
consequently its pulmonary alveoli and blood flow are 
influenced by its concentration and free-form. The 
alkalinity of saliva enhances nicotine absorption, which has 
a 8.02 dissociation constant that splits nicotine into two 
halves, one ionized and one non-ionized, the latter being 
the absorbed form (14). It takes only 15 seconds for 
nicotine to pass the lipophilic blood brain barrier and reach 
50% of its concentration in the cerebral areas (15). Nicotine 
input is regulated by the consumer, by his smoking habits 
(frequency and depth of inhaling), the wellness of the 
pulmonary system, and the environmental quality. After 
absorption, nicotine is highly concentrated in the hepatic 
tissue, kidney, lung, spleen, and slightest concentration in 
fat tissue, whereas for cotinine, the highest concentration is 
found in liver (16). 
Cytochrome P450 2A6/5 (CYP2A6/5), which is part of 
CYP 450 enzyme family, is the main enzyme responsible 
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for nicotine oxidation and it can induce ROS and oxidative 
stress; at the hepatic level, nicotine is C-oxidized and 
inactivated to cotinine and cotinine to 3′-hydroxycotinine 
(3HC) (16). The assessment of the correlations between 
CYP2A6 and renal nicotine clearance has revealed two 
types of smokers: slow nicotine metabolizers and fast 
nicotine metabolizers; fast metabolizers have a higher risk 
of developing addiction and a lower rate of success in 
smoking cessation (17). P450 2A6 and P450 2A13 
enzymes also catalyze nicotine methyl oxidation, resulting 
in nornicotine, N’-nitrosonornicotine, a pulmonary-
specific carcinogenic compound (18). Often, tobacco and 
alcohol are consumed together and they have a mutual 
metabolic influence. Cytochrome P450 2E1 is increased in 
chronic alcohol consumption, and the simultaneous 
consumption of the two substances promotes lipid 
peroxidation, alcoholic fatty liver, and alcoholic cirrhosis 
(19). Alcohol consumption increases fast nicotine removal 
due to the increased activity of the liver CYP2A6 (20, 21). 
CYP2A5 influences the nicotine and cotinine 
bioavailability, expressed by the fact that nicotine’s 
concentration is higher in the brain compared to cotinine, 
because of the slower liver cotinine metabolism and its 
difficulty crossing the brain barrier (22). Nicotine is 
actively transported by the renal cells and because of its 
basic condition, its excretion rate is influenced by urine 
pH, compared to cotinine which is influenced only by the 
urinary flow (23) (Figure 3).  By means of oxidative 
stress, nicotine promotes renal impairment and tubular 
injury, which are expressed more in young renal tissues 
(24). NAChR are present in mesangial cells, proximal 
tubular cells, and podocytes. Nicotine downregulates 
nephrin constitution and increases the pro-apoptotic 
podocyte Bax enzyme and ROS production in a dose-
dependent manner, enhancing the progression of chronic 
renal disease (25). Regarding nicotine and cotinine 
metabolism, factors influencing the compound 
elimination include: grapefruit juice- inhibits hepatic 
enzymes; menthol increases cotinine’s half-life and the 
metabolism of nicotine; women have a higher tobacco-
derived product metabolic rate than men, which is 
accelerated in the presence of oral contraceptives, age-
related delayed clearance; and general diseases that 
include renal failure, alcoholic liver disease, hepatitis, 
associated disease inductor and inhibitor medication; and 
smoking habits (16). 
 
Figure 3. Nicotine metabolism and the pathogenic molecular mechanisms of nicotine addiction    
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1.4 Genetic determinism of nicotine addiction 
Genome-wide association studies (GWAS) have 
assessed single nucleotide polymorphism (SNP) genes 
associated with smoking initiation. Results have shown 
that the following proteins are involved in smoking 
behavior and addiction: glutamate receptor subunits 
(GRIN2A, GRIN2B, GRIK2, and GRM8), cell adhesion 
molecules (CDH23), neurotrophic receptor tyrosine kinase 
(NTRK2), and the growth factor receptor-bound protein 14 
(GRB14) (26). Jensen et al. investigated the relationship 
between smoking and the SNP in protocadherin (PCDH), a 
transmembrane protein present in neural synapses, in 3600 
patients (27). They administered nicotine intravenously 
after an overnight abstinence and their results showed that 
patients with PCDH SNP responded fast and effectively to 
nicotine infusion. GWAS also found an association 
between NACHR subunits (CHRNA3-4-5-6, CHRNB2-3-
4), dopamine b-hydroxylase (DBH), Flavin-containing 
monooxygenase (FMO), and nicotine dependence. 
Smokers with a reduced CYP2A6 allele activity 
(CYP2A6*2, *4, *9, *12) have a slower nicotine metabolic 
rate (a higher plasma nicotine concentration) and a 
decreased hepatic enzyme activity, while CYP2A6*1B 
smokers have a higher metabolic rate (8).   
1.5 Genetic determinism in smoking cessation  
A systematic review of 46 papers on the genetic-
medication interaction reported that several genes were 
involved in nicotine addiction, smoking withdrawal, and 
medication efficacy: CHRNA5-A3-B4, CYP2A6, DBH, 
CHRNA4, COMT, DRD2, DRD4 and CYP2B6 (28). The 
SNP in CYP450 2A6, the enzyme that inactivates nicotine 
to cotinine, is known to have a direct influence on the 
number of smoked cigarettes, smoking behavior, and the 
efficacy of varenicline and bupropion treatments, 
especially in fast nicotine metabolizers compared to slow 
metabolizers. Researchers have also found the genetic 
implication for the dopamine pathway, more precisely 
dopamine COMT enzyme in addiction mechanism (28). 
2. Social context and medical implications 
Smoking habits are influenced by a number of factors 
(29). Agaku et al. collected information from 
Eurobarometer 345 and analyzed the determining smoking 
factors and the marketing and design elements (30). The 
initiation of smoking and the brand’s choice were enhanced 
by the pleasant smell and taste of tobacco, its packaging, 
price, and specific flavors. The analysis further showed that 
attractiveness was increased by the length, diameter, and 
additives such as menthol or cinnamon. Cigarette 
marketing uses terms such as “light”, “organic”, “silver”, 
which have an appealing effect on buyers, and make them 
seem less harmful. The World Health Organization’s 
Directives regulate tobacco products’ design, flavor, and 
marketing, including statements which would influence the 
consumers to choose a specific tobacco brand.  
Chronic nicotine consumption leads to tobacco 
dependence, which pragmatically occurs when the 
individual “desires” a cigar or cigarette. The degree of 
dependence is commonly diagnosed with the Fagerström 
test, which classifies smoking psychiatric disorders, 
anxiety and depression (31). The World Health 
Organization (WHO) states that over a million deaths are 
caused by smoking each year, of which 600,000 are not 
active smokers, and alerts the population that the number 
of consumers is increasing and the initiation age decreases 
(32). The cigar/cigarette smoke and its products induce a 
chronic inflammatory status (33), a continuous increase in 
mortality due to pulmonary obstructive disease, cardiac 
disease, oral cavity and lung cancer, along with other 
cofactors (34, 35). Carcinogenic, irritating, and 
asphyxiating nicotine and other smoke compounds are 
absorbed by means of the pH, so that the high-soluble 
substances are absorbed in the upper airways, whereas less 
soluble substances are absorbed in the pulmonary cells 
(36). Nicotine’s cytotoxic effect on oral cavity structures 
has been tested on human periodontal stem cells (37). 
Different nicotine concentrations induced autophagic 
activity, decreased periodontal stem cells viability, and 
altered the periodontium cell turnover, which, when taken 
into account, induces and aggravates the periodontal 
disease. Oral hygiene and exhaled carbon monoxide were 
assessed on a group of 65 subjects (50 smokers, 15 non-
smokers) (38). Plaque, gingival calculus index, and CO 
were recorded. The degree of nicotine dependence was 
evaluated using the Fageström test. The study showed that 
Fagerström scores were directly related to daily tooth brush 
frequency and gingival index. Smoking was positively 
correlated with bad oral hygiene as indicated by gingival, 
plaque, and calculus indices. 
3. The correlation between nicotine and Advanced 
Glycation End Products (AGEs)  
Advanced glycation end products (AGEs) are final 
products of Maillard reaction; in a medical context, AGEs 
have been associated with the enhanced production of 
reactive oxygen species (ROS), and the subsequent 
generation of oxidative or carbonyl stress, thus leading to 
an inflammatory response. AGEs encompass a large group 
of products, of which pentosidine, carboxymethyllysine 
(CML), glyoxal-lysine dimer (GOLD), and methylglyoxal 
(MG) have been intensely investigated (39). Based on their 
source, two classes of AGEs are known: the endogenous 
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AGEs (formed in oxidative stress conditions, 
hyperglycemia) and exogenous AGEs: dietary AGEs 
(dAGEs). Moreover, AGEs can be produced by UV 
(ultraviolet) radiation, nicotine and cigarette smoke, and 
microwaves and ultrasounds (40). Smoking AGEs are 
formed in several hours and bind to connective tissue 
collagen fibers, leading to increased tissue hardness. 
AGEs mainly act through an immunoglobulin surface 
receptor (RAGE) mechanism and induce chronic 
inflammation. Nicotine and nornicotine are enhancing 
factors for the tissular expression of AGEs. Sanders et al. 
has shown that gingival epithelial cells exposed to 
cigarette smoke extract (CSE) exhibited increased RAGE 
and cytokine mediated inflammatory response, including 
Ras and nuclear factor kappa B (NF- B) pathways. This 
research group used semi-synthetic glycosaminoglycan 
ethers (SAGEs) and demonstrated the inhibitory effect on 
AGEs due to the decreased effect on cytokine production 
in cells stimulated by CSE (41). Chapman et al. evaluated 
the effect of SAGE in oral squamous cell carcinoma 
(OSCC) cells exposed to CSE in different concentrations 
(0.05%, 0.1%, 0.2%, and 0.5%) (42). Smoke extract 
increased AGEs expression and OSCC cell proliferation. 
The removal of etiological CSE and SAGE treatment 
decreased the inflammatory response (the production of 
matrix metalloproteinases 2, 9, 14) and induced OSCC 
cell downregulation (Figure 4).  
An in vitro study regarding the effect of CSE on rat 
alveolar epithelial cell lines showed that CSE activated 
RAGE; Ras is involved in cell growth and differentiation; 
and NF- B is related to carcinogenesis and cancer 
progression (43). Marinucci et al. investigated nicotine, 
methylglyoxal (MG), a component of cigarette smoke, 
and AGEs effect on the differentiation and proliferation 
of human osteoblastic cells, with the focus on 
osteoporosis (44). They also pretreated osteoblasts with 
Tiron- an antioxidative and AG- scavenger for MG and 
its derivatives (MG-H1). Nicotine induced a dose- and 
time-dependent increase in RAGE and hydrogen peroxide 
(H2O2). Tiron reduced nicotine induced-apoptosis and 
the AG pretreatment showed the involvement of MG-H1 
in RAGE overexpression and cellular apoptosis. The 
accumulation of tobacco-sourced AGEs in the skin can be 
assessed by using the autofluorescence (SAF) technique. 
Waateringe et al. used the AGE Reader to assess skin 
AGEs derived from active and secondhand cigarette 
smoke exposure, along with smoking withdrawal, in 
healthy individuals and diabetic patients (45). High SAF 
levels were correlated with diabetic active smokers and 
SAF intensity was correlated with the hours of cigarette 
smoke exposure. In contrast, cigarette cessation led to 
SAF decrease. The authors stated that for a former 
smoker, it takes approximately 15 years to reach the same 
SAF levels as a non-smoker. 
4. Treatment strategy in nicotine addiction 
In the National Socialist Germany, smoking was 
considered to be un-Aryan, and thus smoking cessation 
was politically driven. However, the efforts were not 
effective, because of the stressful living conditions and 
because cigarettes were used as postwar commercial goods 
(46). After establishing the direct relationship between 
cigarette smoke and lung cancer, surveys (47) and research 
studies regarding smoking and its effects on human 
physical and mental health were initiated. The most widely 
used and effective methods in smoking cessation were 
nicotine patches, bupropion, and varenicline FDA 
approved medication, sometimes in conjunction with 
cognitive/active therapy. Varenicline is a partial antagonist 
which binds to nicotine acetylcholine (ACh) receptors and 
inhibits the activation of the ACh receptor by nicotine, 
leading to the lack of satisfaction while smoking (48). 
Varenicline has a high affinity for a4ß2 nicotinic receptors, 
blocking the addictive effect of nicotine; this medication 
has the role of increasing dopamine in the cerebral 
rewarding areas usually occupied by nicotine (49). A study 
on 213 subjects compared the effectiveness of pre-quit 
patches, varenicline (2 weeks before/10 weeks after 
smoking cessation), and classical patches (50). The 
pretreatment reduced smoking satisfaction and thus led to 
a decrease in the number of smoked cigarettes. A more 
invasive study investigated Nicotine Replacement Therapy 
(NRT) using high dose nicotine patches (21-84 mg/day) for 
smoking cessation, without interrupting conventional 
smoking (51). Researchers found a reduction in pleasure 
and the number of smoked cigarettes and reported no 
relapse during the post therapeutic 4 weeks. The results 
were attributed to the combined effect of high nicotine 
dose: a nicotine patch pre-load bound to ACo receptors, 
which led to an unpleasant sensation while inhaling and a 
secondary side effect of a nicotine overload causing mild 
nausea or vomiting (51). Other widely used NRT methods 
are nicotine gum, nicotine inhaler, nicotine nasal spray, 
where the nicotine inhaler provides up to 4 mg of nicotine, 
which alone is not enough for a current smoker attempting 
to quit. The author’s analysis showed that combining 
nicotine patches with the inhaler increases the success rate 
by two times. Caldwell stated that for achieving the 
pleasant feeling, nicotine must pass through the pulmonary 
route, and the association of a metered dose inhaler with 
nicotine patches is a successful therapeutic approach (52). 
Anida-Maria Băbțan et al. 
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The spray and the inhaler’s particularity is the fact that their 
deposition is mainly in the upper airways, while the inferior 
pulmonary structures are spared, which represents a 
positive feature especially in pulmonary obstructive 
diseased chronic consumers (53).  Active nicotine spray 
associated with patches showed a prolonged period of 
rebound compared to patches only (54, 55). The effect of 
the sublingual nicotine tablet was compared to transdermal 
patches, associated with moderate psychological 
counseling (56).  
In a mice model study, Saravia et al. investigated the 
correlation between nicotine withdrawal and microglial 
activation in prefrontal cortex and hippocampus, and the 
effect of cannabidiol in redressing the cognitive damage 
induced by cessation (57). Inflammatory proteins TNF-α, 
IL-1ß, IL-10, and IFN increased in hippocampus and 
prefrontal cortex stratum pyramidal on the 4th day after 
nicotine withdrawal, while cannabidiol post-treatment 
normalized TNF-α and IL-1ß levels. The authors suggested 
that nicotine withdrawal syndrome altered neurogenesis by 
enhancing the expression of inflammatory proteins, while 
cannabinoids had a protective effect on cognition 
impairment. In the same contextual area, Johnson et al. 
investigated the implication of psilocybin in nicotine 
withdrawal, the abstinence time, or the reduction in the 
number of smoked cigarettes in a survey on 358 subjects 
(58). The authors stated that the 5-HT2A 5-HT1A could 
exert a psychedelic and endorphin-serotonin releasing 
effect. Most of the subjects reported a decrease in the 
number of smoked cigarettes or longer periods of 
abstinence after the psychedelic experience. The delayed 
psilocybin effect could alleviate several withdrawal 
symptoms involving anxiety and craving, and could also 
exert a parasympathomimetic effect. A meta-analysis by 
Klinsophon et al. performed on 19 studies focusing on the 
effect of physical activity on smoking cessation did not 
reach clear conclusions due to the controversies regarding 
ß-endorphins release after physical exercise (59).  
However, the results showed that aerobic and resistance 
exercises improved the patient’s mood, whereas yoga and 
similar breathing and relaxing exercises led to stress 
reduction, thus suggesting that parasympathetic stimuli had 
a positive effect on smoking cessation.  
Cigarette/cigar smoke’s first contact is with the oral 
cavity’s structures. The negative effect of smoking on the 
oral mucosa, periodontium, and bone quality and quantity 
is undisputed, due to the nicotine’s toxic metabolites and 
chronic inflammatory local response. Tobacco-induced 
local pathology comprises dental caries, tobacco stains, 
halitosis, hairy tongue, stomatitis, premalignant or 
malignant lesions (60). The American Dental Association 
(ADA) has suggested that dentists have the opportunity of 
helping addicts in cessation therapy by using the 5-A 
strategy: Ask, Advise, Assess, Assist, Arrange follow-up 
(61). They can intervene positively because of the multiple 
visits of the patient to the dental clinic for a direct control 
of the oral and systemic health outcome. The dentist can 
make patients aware of their oral health condition which 
may be affected by smoking, especially periodontal 
diseases, and the importance of cessation and the absence 
of relapse in preserving dental treatment outcomes and 
systemic conditions as well (62).  
Due to the technological era and the heavy use of 
smartphones, smoking cessation applications were 
considered a positive approach to improving cessation 
therapy results and a long-term abstinence period, 
especially in adolescents and young adults. The medical 
theory, the epidemiological data, the psychotherapeutic 
aspects, and the user’s needs were involved in developing 
theses apps (63, 64). The apps permit the patient to keep a 
diary of the symptoms associated with quitting, the 
quantification of the achievements the addict accumulates 
during the therapy and especially after, and the online 
psychotherapeutic characteristics (65). The interactive 
nature of these applications showed increased patient 
compliance after NRT therapy, with potential value for 
such programs either as complementary or as a sequence in 
smoking cessation programs (66). 
4.1. Electronic cigarettes (ECs) – a healthier alternative? 
ECs originally emerged as a healthier alternative to 
conventional smoking. ECs contain tobacco specific 
ingredients and flavors and include the following 
components: a vaporizer with a heating mechanism, a 
cartridge and a battery. The higher the voltage, the greater 
the production of vapors and carcinogenic compounds 
(67). EC-liquids include nicotine, propylene glycol (PG), 
vegetable glycerin (VG), and flavors. DeVito et al. found 
that PG/VG ratio influenced the nicotine input and the 
concentration of toxic compounds (68). UK Health 
Ministry asserted that EC vapors contain 95% fewer 
noxious products than regular cigarette smoke (69). EC 
vapors also contain nitrosamines, alkaloids, and turpentine 
(used either as a solvent or as a scent for a pleasant 
fragrance). Löhler and Wollenberg investigated the 
differences between classic and electronic cigarettes and 
their influence on adolescents’ and adults’ behavior. Their 
results showed that most of the adult consumers had chosen 
to adopt ECs due to their lower negative biological effects, 
or as a way to reduce and quit smoking; another reason was 
the possibility of smoking in restricted areas. In contrast, 
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adolescent consumers considered ECs the initial stage, 
preceding conventional smoking; the risk of changing the 
ECs for conventional smoking seemed to be correlated 
with the social, economic and educational status (70). 
4.2.  Old habits die hard - perspectives? 
Nicotine addiction has a multifactorial etiology, from 
genetic determinants to the context of social acceptance. 
Daily stress has an obvious impact on the frequency and 
quantity of nicotine use. Several studies have described the 
mechanisms of the three stages of nicotine addiction, from 
the wanting level (self-control) to the craving level in 
which the receptors and the autonomic nervous system take 
control. Cigarette consumers seem to ignore the 
progressive multisystem alterations induced by the 
metabolism of nicotine and smoke components 
(carcinogens, AGEs-MG, asphyxiants, proinflammators, 
irritants). Moreover, it is well known that second-hand and 
third-hand smoke induce negative delayed effects in non-
smokers. The ECs are error-inducers for their users, 
especially due to the design and the lack of smoke 
elimination. Nicotine addiction is insidious and tricks 
patients by an apparent self-control on cigarette input. 
Clinical studies investigating several single or associated 
cessation therapies have demonstrated that bupropion, 
varenicline, and nicotine patches had increased efficacy, 
and could be combined with physical/psychical therapy. 
However, there are no studies on long-term follow-up. It is 
not known when the relapse key moment occurs and 
especially why many people who had given up smoking 
eventually return to their unhealthy habit. There is no 
certain quantity of nicotine or number of smoked cigarettes 
which make a person become an addict. Further 
investigations are needed to clarify the neural and 
psychical factors that cause nicotine addiction and, most 
importantly, the relapse mechanisms. 
Discussions 
Biosensors, nicotine assessment and NRT 
In biofluids, biomarkers can be used to evaluate the 
exposure, accumulation of nicotine, and cigarette smoke 
byproducts, such as aromatic amines, polycyclic aromatic 
hydrocarbons, acrylamide, benzene, and crotonaldehyde, 
as well as the efficacy of cessation therapy (71). The 
assessment was performed using different techniques: 
liquid chromatography and immunochromatography, in 
which cotinine is gold labeled nanoparticles combined with 
an image sensor to quantify the signal of the bounded 
product (72). Cotinine was mainly chosen as a tobacco 
biomarker because of the differences between the half-life 
of the two substances, 2 hours for nicotine and 
approximately 20 hours for cotinine. The accumulation of 
nicotine and cotinine in deciduous teeth was assessed using 
gas chromatography/bmass spectrometry (GC/MS) and 
liquid chromatography (LC)- tandem mass spectrometry 
(MS/MS) to monitor tobacco exposure and the cumulative 
effect of nicotine. To evaluate the efficacy of the cessation 
therapy, nicotine and cotinine can be analyzed in biological 
fluids such as saliva and urine. Salivary mouth swab (Oral 
Fluid Device) cotinine tests were shown to give accurate 
results of tobacco exposure, in both conventional cigarettes 
and ECs, even in the case of delayed analysis of the 
samples (73). It was shown that the concentration of 
nicotine is higher in unstimulated saliva, and cotinine’s 
concentration in stimulated saliva, because of the 
differences in the salivary pH and tobacco’s ionized and 
non-ionized metabolites (74). Synthetic receptors, 
molecularly imprinted polymers bound to nicotine and 
immobilized to quartz crystal and analyzed using quartz 
crystal microbalance-dissipation (QCM-D) sensor, use the 
viscoelastic properties of the investigated substances (75). 
Researchers developed the molecularly imprinted 
polymer-carbon nanotube sensor either for the 
electrochemical heat-transfer-resistance based cotinine 
detection or for quantification by using the electrical 
resistance to the substance (76, 77). 
Thus, numerous techniques are available for detecting 
and quantifying nicotine and its metabolites as markers of 
exposure or for evaluating and monitoring the cessation 
treatment. There are various treatment approaches, 
including pharmaceutic nicotine antagonists, NRT using 
patches, gum, inhalers, sprays, drops, combined with 
psychotherapy and newly introduced phone applications. 
The majority of treatment methods use an oral 
administration route due to the rapid absorption of nicotine 
through the mucosa in the blood flow. One important 
negative aspect is the compliance of the patient, because 
the substances are mainly home self-medications. One 
patient might underdose, which results in withdrawal 
symptoms and a higher risk of relapse, or overdose, which 
is not an effective step for ending the habit. To the best of 
our knowledge, there is no intraoral device to provide 
real-time nicotine or cotinine levels. Such a device should 
be personalized, obtained through the interdisciplinary 
relation between the dentist and the technician or the 
orthodontist (78), and adapted to the anatomical 
characteristics of the patient’s oral cavity. It could be 
represented by a prosthetic piece, for example, a mouth 
guard made from a biocompatible material in which a 
small-dimensioned biosensor can be attached (79). For 
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accurate results, the miniaturized device should be 
capable of acquiring the essential information, measuring 
the nicotine level in saliva by processing the received 
data, and transmitting the results remotely, either wired 
or mobile. The biosensor would assess real-time salivary 
smoking biomarkers. For a lightweight, easy-handling 
device, the power supply should be wireless and small. 
Various battery dimensions and power are available for 
medical applications that have low-power consumption - 
2uW at 1.2V, so the battery would be active for 6-7 
months. Small sized wireless batteries (2 square 
millimeters) can provide energy from active radio waves 
(80). Engineers have developed a 3D holographic 
lithography with a 2D photolithography micro battery, 
less than 2 inches in dimension, which includes a high-
energy material—tin—providing a long-life battery (81). 
A significant challenge in miniaturizing the device lies in 
the transmission step, in which an antenna is needed, a 
component which is difficult or impossible to be 
miniaturize. Due to the high-frequency of the smartphone 
use by consumers, the results could be transferred by 
using an analogue-to-digital convertor, connected by 
Bluetooth to a phone application (82).  
In this manner, the user of the device would know 
when a new nicotine dose is scheduled, without regard to 
his own thought processes or clinical symptomatology. 
The above described nicotine investigation assays are 
summarized in Table 1.  
Table 1. Saliva, nicotine assessment and biosensors 
A useful and innovative approach would be for the 
nicotine’s biosensor prosthetic device to present an alert 
system, which activates the release of a nicotine dose from 
a reservoir into the oral cavity where it will be easily 
absorbed. The dentist could play an important role in 
monitoring, counseling the patient, and ensuring 
maintenance of the device. The information provided by 
the biosensor could be transmitted to the doctor’s 
computing device. The approach would provide a valid, 
accurate, real-time, and non-invasive evaluation of 
nicotine use. Its non-invasive properties, combined with 
NRT, could offer an attractive strategy for both the patient 
and the physician. Saliva-stimulating slow and gradual 
nicotine release from a prosthetic device active biosensor 
would allow a real-time adjusted cure dosage as part of the 
therapy. This could lead to a possible home-based therapy 
in which both the attending physician and the patient could 
have access to the evidence and treatment evolution. 
Conclusions 
Nicotine has drawn researchers’ attention after the 
findings regarding the correlation between smoking and 
pulmonary and other diseases. Smoking addiction has 
strong pharmacological, psycho-social, and media support. 
Evidence has shown that cigarette/cigar smoke and its 
products simultaneously induce and aggravate multiple 
pathologies, beginning with direct contact with the oral 
mucosa and the upper respiratory airways, to tumoral 
disease and addictive behavior. Smoking cessation 
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strategies have a success rate strongly dependent on the 
patient’s compliance. The development of a double-effect 
salivary biosensor could represent a useful approach in 
nicotine addiction therapy, both in the real-time monitoring 
of nicotine levels and in precise nicotine dose 
administration. This approach represents an innovative and 
appealing approach in NRT. Future studies would need to 
demonstrate the device’s efficacy and the patient’s 
compliance to such device treatment options. 
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